Inventor · disambiguated record
Benjamin Wolozin
Also filed as: WOLOZIN BENJAMIN · WOLOZIN BENJAMIN L
6 granted patents·4 pending applications·173 citations·filing 1990–2016
85Inventor score
Files withAQUINNAH PHARMACEUTICALS INC2PANACEA PHARMACEUTICALS INC2EINSTEIN COLL MED1NYMOX CORP1US HEALTH1
Top patents by PatentIndex Score
10 records- 0191US6780971B2Compositions for inhibiting the aggregation pathway of α-synucleinPANACEA PHARMACEUTICALS INC·Filed 2001·Granted Aug 24, 2004·51 cites·4 claims
- 0280US5811310AThe Alz-50 monoclonal antibody and diagnostic assay for alzheimer's diseaseEINSTEIN COLL MED·Filed 1994·Granted Sep 22, 1998·47 cites·5 claims
- 0379US6472421B1Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitorNYMOX CORP·Filed 1998·Granted Oct 29, 2002·53 cites·22 claims
- 0473US9359363B2Identification of compounds that disperse TDP-43 inclusionsWOLOZIN BENJAMIN·Filed 2012·Granted Jun 7, 2016·2 cites·15 claims
- 0571US7605133B2Isolated peptides to treat alpha-synuclein diseasesPANACEA PHARMACEUTICALS INC·Filed 2004·Granted Oct 20, 2009·2 cites·12 claims
- 0657US5869266AHuman olfactory neuron cultures to diagnose Alzheimer's diseaseUS HEALTH·Filed 1990·Granted Feb 9, 1999·18 cites·3 claims
- 0747US2005149997A1Sterilization of marine organisms by manipulation of DNA contentFiled 2004·Application pending·0 cites
- 0846US2017088515A1Identification of compounds that disperse tdp-43 inclusionsAQUINNAH PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 0937US2019142860A1Nucleic acid based tia-1 inhibitorsAQUINNAH PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1028US2003037344A1Method for evaluating the ability of a compound to inhibit neurotoxicityFiled 1997·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Benjamin Wolozin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →